{"protocolSection":{"identificationModule":{"nctId":"NCT02082210","orgStudyIdInfo":{"id":"15246"},"secondaryIdInfos":[{"id":"I4C-MC-JTBF","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer","officialTitle":"A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer"},"statusModule":{"statusVerifiedDate":"2018-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-03-07","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-12-05","type":"ACTUAL"},"completionDateStruct":{"date":"2018-01-24","type":"ACTUAL"},"studyFirstSubmitDate":"2014-03-06","studyFirstSubmitQcDate":"2014-03-06","studyFirstPostDateStruct":{"date":"2014-03-10","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-11-24","resultsFirstSubmitQcDate":"2020-11-24","resultsFirstPostDateStruct":{"date":"2020-12-19","type":"ACTUAL"},"dispFirstSubmitDate":"2018-11-30","dispFirstSubmitQcDate":"2018-11-30","dispFirstPostDateStruct":{"date":"2018-12-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-11-24","lastUpdatePostDateStruct":{"date":"2020-12-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer. In Part A of this study, escalating doses of Emibetuzumab will be given in combination with a fixed dose of ramucirumab to evaluate the safety of the combination. After a recommended schedule and dose range of Emibetuzumab and ramucirumab has been established, Part B of the study will confirm safety and to see how well certain tumors respond to the combination of study drugs. The average amount of time on study is expected to be about 6 months."},"conditionsModule":{"conditions":["Advanced Cancer","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Hepatocellular Cancer","Renal Cell Carcinoma","Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":97,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Emibetuzumab + Ramucirumab (Part A)","type":"EXPERIMENTAL","description":"Part A: Dose escalation (750mg, 2000mg) of Emibetuzumab administered intravenously (IV), on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.","interventionNames":["Drug: Emibetuzumab","Drug: Ramucirumab"]},{"label":"Emibetuzumab + Ramucirumab (Part B)","type":"EXPERIMENTAL","description":"Part B: Recommended 750mg Emibetuzumab dose from Part A to be administered IV, on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.","interventionNames":["Drug: Emibetuzumab","Drug: Ramucirumab"]}],"interventions":[{"type":"DRUG","name":"Emibetuzumab","description":"Administered Intravenously (IV)","armGroupLabels":["Emibetuzumab + Ramucirumab (Part A)","Emibetuzumab + Ramucirumab (Part B)"],"otherNames":["LY2875358"]},{"type":"DRUG","name":"Ramucirumab","description":"Administered Intravenously (IV)","armGroupLabels":["Emibetuzumab + Ramucirumab (Part A)","Emibetuzumab + Ramucirumab (Part B)"],"otherNames":["LY3009806","IMC-1121B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)","description":"DLT is defined as an adverse event during Cycle1 that is possibly, probably, or definitely related to treatment with Emibetuzumab in combination with fixed regimen of Ramucirumab \\& fulfills any 1 of the following criterion using NCI CTCAE Version 4.03:\n\nGrade 3 non-hematological toxicity. Exceptions will be made for:Nausea, vomiting, diarrhea, constipation, or skin rash that persists for ≤3 days following appropriate supportive care intervention. Grade 3 hypertension in which systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg persist \\<7 days after intensified antihypertensive therapy is initiated.\n\nGrade 4 hematological toxicity of ≥7 days duration.\n\n≥Grade 3 thrombocytopenia with ≥Grade 2 bleeding.\n\nAny febrile neutropenia.\n\nAny other significant toxicity deemed by the primary investigator \\& Lilly clinical research personnel to be dose-limiting (eg, any toxicity that is possibly related to the study medication that requires the withdrawal of participant from study Cycle1).","timeFrame":"Baseline through Cycle 1 (28 day cycle)"},{"measure":"Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]","description":"ORR is the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","timeFrame":"Baseline through Measured Progressive Disease or Death (Up to 17 months)"}],"secondaryOutcomes":[{"measure":"Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab","description":"Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab.","timeFrame":"Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose"},{"measure":"Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR])","description":"DCR is the proportion of participants who exhibit a SD or confirmed CR or PR relative to baseline. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","timeFrame":"Baseline through Measured Progressive Disease (Up to 17 months)"},{"measure":"Part B: Progression Free Survival (PFS)","description":"PFS was defined as the time from the date of first dose of study drug until first observation of objective (radiographically documented) PD as defined by RECIST v1.1 or death from any cause, whichever comes first. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","timeFrame":"Baseline to Measured Progressive Disease or Death (Up to 17 Months)"},{"measure":"Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab","description":"Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) from time zero to tlast of Emibetuzumab.","timeFrame":"Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose"},{"measure":"Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab","description":"Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab.","timeFrame":"Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose"},{"measure":"Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies","description":"Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:4 for anti-emibetuzumab antibodies).","timeFrame":"Baseline through 46 Months"},{"measure":"Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab","description":"Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab.","timeFrame":"Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose"},{"measure":"Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies","description":"Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:10 for anti-ramucirumab antibodies).","timeFrame":"Baseline through 46 Months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must have histological or cytological confirmed diagnosis of the following tumor types that is advanced and/or metastatic cancer and must be, in the judgment of the investigator, an appropriate participant for experimental therapy\n\n  * Part A: Any type of solid tumor (\"all comer\")\n  * Part B1: Gastric or Gastroesophageal Junction (GEJ) adenocarcinoma\n  * Part B2: Hepatocellular cancer (excluding fibrolamellar carcinoma)\n  * Part B3: Renal cell carcinoma (any histology)\n  * Part B4: Non-small cell lung cancer (squamous or non-squamous)\n* Have at least 1 measurable lesion outside of the central nervous system (CNS) whose presence is assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Availability of a tumor sample taken after progression on the most recent line of systemic tumor therapy or willing to undergo a tumor biopsy pre-study treatment.\n* Have a performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale in Part A and ≤ 1 on the ECOG scale in Part B.\n* Have adequate organ function.\n* Routine urinalysis showing ≤1+ protein or protein/creatinine ratio \\<0.5. For proteinuria ≥2+ or urine protein/creatinine ratio ≥0.5, 24-hour urine must be collected and the level must be \\<1 gram of protein in 24 hours for subject enrollment.\n* Have discontinued all previous cancer therapies and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 halflives prior to study enrollment, whichever is shorter, and recovered from the acute effects for therapy.\n* Have an estimated life expectancy, in the judgment of the investigator, that will permit the participant to complete 8 weeks (2 cycles) of treatment.\n* Males and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for at least 3 months following the last dose of study drug. Females with childbearing potential must have had a negative serum pregnancy test 7 days before the first dose of study drug and must not be breast-feeding.\n\nExclusion Criteria:\n\n* Have serious pre-existing medical conditions (at the discretion of the investigator, such as severe acute or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation).\n* Have a history of hypertensive crisis or hypertensive encephalopathy or current poorly controlled hypertension despite standard medical management.\n* Participant has experienced any arterial thromboembolic event (ATE), including myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack, within 6 months prior to receiving study drugs.\n* Have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolic event during the 3 months prior to receiving study drugs.\n* Are receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or similar agents. Participants receiving prophylactic, low-dose anticoagulation therapy are eligible provided that they are on low-molecular weight heparin or oral factor Xa inhibitors.\n* The participant is receiving chronic therapy with nonsteroidal anti-inflammatory drugs or other antiplatelet agents. Aspirin use at doses up to 325 mg/day is permitted.\n* Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to receiving study drugs.\n* Have a history of GI perforation and/or fistulae within 6 months prior to receiving study drugs.\n* Have congestive heart failure (CHF) New York Heart Association class ≥3 or symptomatic or poorly controlled cardiac arrhythmia.\n* Have undergone major surgery within 28 days prior to receiving study drugs.\n* Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to receiving study drugs.\n* Have a known active fungal, bacterial, and/or known viral infection. Hepatocellular cancer participants with chronic viral (B or C) hepatitis are eligible if they retain adequate liver function.\n* Have liver cirrhosis with a Child-Pugh Stage of B or C.\n* Have symptomatic CNS malignancy (with the exception of medulloblastoma) or metastasis.\n* Have corrected QT (QTc) interval of \\>470 milliseconds on screening electrocardiogram (ECG).\n* Have received previous treatment with ramucirumab or Emibetuzumab, except for participants enrolled in cohort B1 (Gastric or GEJ adenocarcinoma) and B4 (non- small cell lung cancer) who may have received previous ramucirumab treatment.\n* Known hypersensitivity to any of the treatment components of ramucirumab or Emibetuzumab.\n* Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results.\n* Are pregnant or breastfeeding.\n* For Part B4 (non-small cell lung cancer) only:\n\n  * The participant has radiologically documented evidence of major blood vessel invasion or encasement by cancer\n  * Participants with a history of gross hemoptysis within 2 months prior to study treatment\n  * The participant has radiographic evidence of intratumor cavitation, regardless of tumor histology","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Massachusetts General Hospital","city":"Boston","state":"Massachusetts","zip":"02114-3117","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Dana Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Memorial Sloan Kettering Cancer Center","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Tennessee Oncology PLLC","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Click here for more information about this study: A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer","url":"https://www.lillytrialguide.com/en-US/studies/solid-tumor/JTBF#?postal="}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Two part study, Part A with 2 cohorts (750 milligram (mg), 2000mg) \\& Part B with four tumor specific cohorts (gastric, hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC)).","recruitmentDetails":"Part A: Completers are those who have completed one cycle of treatment. Part B: Completers are those who 1)Have measurable disease at baseline and at least one post-baseline tumor assessment; and 2) Were treated until PD or death, or discontinued due to an AE and completed the required follow-up.","groups":[{"id":"FG000","title":"Part A - 750 mg Emibetuzumab","description":"Participants received 8 milligram per kilogram (mg/kg) Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"FG001","title":"Part A - 2000 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 2000 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"FG002","title":"Part B - Gastric","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"FG003","title":"Part B - HCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"FG004","title":"Part B - RCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"FG005","title":"Part B - NSCLC","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"16"},{"groupId":"FG003","numSubjects":"45"},{"groupId":"FG004","numSubjects":"15"},{"groupId":"FG005","numSubjects":"15"}]},{"type":"Received at Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"16"},{"groupId":"FG003","numSubjects":"45"},{"groupId":"FG004","numSubjects":"15"},{"groupId":"FG005","numSubjects":"15"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"39"},{"groupId":"FG004","numSubjects":"12"},{"groupId":"FG005","numSubjects":"13"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"2"}]},{"type":"Clinical Progression","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"No Post-Baseline Tumor Assesment","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Part A - 750 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"BG001","title":"Part A - 2000 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 2000 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"BG002","title":"Part B - Gastric","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"BG003","title":"Part B - HCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"BG004","title":"Part B - RCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"BG005","title":"Part B - NSCLC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"15"},{"groupId":"BG006","value":"97"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"15"},{"groupId":"BG006","value":"97"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"41.3","spread":"20.6"},{"groupId":"BG001","value":"62.0","spread":"13.5"},{"groupId":"BG002","value":"62.6","spread":"9.1"},{"groupId":"BG003","value":"63.4","spread":"9.5"},{"groupId":"BG004","value":"63.1","spread":"10.1"},{"groupId":"BG005","value":"59.9","spread":"8.6"},{"groupId":"BG006","value":"62.0","spread":"10.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"15"},{"groupId":"BG006","value":"97"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"27"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"34"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"70"}]}]}]},{"title":"Ethnicity (NIH/OMB)","populationDescription":"All participants with baseline ethnicity data.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"39"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"90"}]}],"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"6"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"36"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"84"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","populationDescription":"All randomized participants with baseline race data.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"14"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"92"}]}],"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"9"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"6"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"32"},{"groupId":"BG004","value":"14"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"76"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"United States","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"15"},{"groupId":"BG006","value":"97"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"15"},{"groupId":"BG006","value":"97"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)","description":"DLT is defined as an adverse event during Cycle1 that is possibly, probably, or definitely related to treatment with Emibetuzumab in combination with fixed regimen of Ramucirumab \\& fulfills any 1 of the following criterion using NCI CTCAE Version 4.03:\n\nGrade 3 non-hematological toxicity. Exceptions will be made for:Nausea, vomiting, diarrhea, constipation, or skin rash that persists for ≤3 days following appropriate supportive care intervention. Grade 3 hypertension in which systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg persist \\<7 days after intensified antihypertensive therapy is initiated.\n\nGrade 4 hematological toxicity of ≥7 days duration.\n\n≥Grade 3 thrombocytopenia with ≥Grade 2 bleeding.\n\nAny febrile neutropenia.\n\nAny other significant toxicity deemed by the primary investigator \\& Lilly clinical research personnel to be dose-limiting (eg, any toxicity that is possibly related to the study medication that requires the withdrawal of participant from study Cycle1).","populationDescription":"All participants who received at least one dose of Emibetuzumab in Part A \\& Part B.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Baseline through Cycle 1 (28 day cycle)","groups":[{"id":"OG000","title":"Part A - 750 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG001","title":"Part A - 2000 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 2000 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG002","title":"Part B - Gastric","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG003","title":"Part B - HCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG004","title":"Part B - RCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG005","title":"Part B - NSCLC","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]","description":"ORR is the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","populationDescription":"All participants who received at least one dose of Emibetuzumab in Part B.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline through Measured Progressive Disease or Death (Up to 17 months)","groups":[{"id":"OG000","title":"Part B - Gastric","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG001","title":"Part B - HCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG002","title":"Part B - RCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG003","title":"Part B - NSCLC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0","upperLimit":"30"},{"groupId":"OG001","value":"6.7","lowerLimit":"0","upperLimit":"20"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"20"},{"groupId":"OG003","value":"6.7","lowerLimit":"0","upperLimit":"30"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab","description":"Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab.","populationDescription":"All participants who received at least one dose of Emibetuzumab and had evaluable PK samples in Part A \\& Part B.\n\nPer protocol analysis was performed per each dose irrespective of the study parts.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Microgram per milliliter (µg/mL)","timeFrame":"Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose","groups":[{"id":"OG000","title":"All Parts - 750 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG001","title":"All Parts - 2000 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 2000 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":"27"},{"groupId":"OG001","value":"575","spread":"33"}]}]}]},{"type":"SECONDARY","title":"Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR])","description":"DCR is the proportion of participants who exhibit a SD or confirmed CR or PR relative to baseline. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","populationDescription":"All participants who received at least one dose of Emibetuzumab in Part B.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline through Measured Progressive Disease (Up to 17 months)","groups":[{"id":"OG000","title":"Part B - Gastric","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG001","title":"Part B - HCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG002","title":"Part B - RCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG003","title":"Part B - NSCLC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","lowerLimit":"20","upperLimit":"80"},{"groupId":"OG001","value":"60","lowerLimit":"40","upperLimit":"70"},{"groupId":"OG002","value":"46.7","lowerLimit":"20","upperLimit":"70"},{"groupId":"OG003","value":"86.7","lowerLimit":"60","upperLimit":"100"}]}]}]},{"type":"SECONDARY","title":"Part B: Progression Free Survival (PFS)","description":"PFS was defined as the time from the date of first dose of study drug until first observation of objective (radiographically documented) PD as defined by RECIST v1.1 or death from any cause, whichever comes first. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","populationDescription":"All participants who received at least one dose of Emibetuzumab in part B. Censored participants in Part B- Gastric = 4; Part B - HCC = 15; Part B - RCC = 7; Part - B NSCLC = 4;","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to Measured Progressive Disease or Death (Up to 17 Months)","groups":[{"id":"OG000","title":"Part B - Gastric","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG001","title":"Part B - HCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG002","title":"Part B - RCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG003","title":"Part B - NSCLC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.64","lowerLimit":"1.35","upperLimit":"4.60"},{"groupId":"OG001","value":"5.42","lowerLimit":"1.64","upperLimit":"8.12"},{"groupId":"OG002","value":"2.92","lowerLimit":"1.18","upperLimit":"7.39"},{"groupId":"OG003","value":"6.57","lowerLimit":"2.86","upperLimit":"9.66"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab","description":"Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) from time zero to tlast of Emibetuzumab.","populationDescription":"All participants who received at least one dose of Emibetuzumab and had evaluable PK samples in Part A \\& Part B.\n\nPer protocol, analysis was performed per each dose irrespective of study parts.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Microgram * hour per milliliter(µg*h/mL)","timeFrame":"Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose","groups":[{"id":"OG000","title":"All Parts - 750 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG001","title":"All Parts - 2000 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 2000 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29800","spread":"26"},{"groupId":"OG001","value":"86500","spread":"25"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab","description":"Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab.","populationDescription":"Noncompartmental PK parameters were not generated for Ramucirumab due to inadequate PK sampling.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose","groups":[{"id":"OG000","title":"All Parts - 750mg","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG001","title":"All Parts - 2000mg","description":"Participants received 8 mg/kg Ramucirumab followed by 2000 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies","description":"Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:4 for anti-emibetuzumab antibodies).","populationDescription":"All participants who received at least one dose of Emibetuzumab and had evaluable immunogenicity samples.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Baseline through 46 Months","groups":[{"id":"OG000","title":"Part A - 750 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG001","title":"Part A - 2000 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 2000 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG002","title":"Part B - Gastric","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG003","title":"Part B - HCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG004","title":"Part B - RCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG005","title":"Part B - NSCLC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"42"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab","description":"Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab.","populationDescription":"Noncompartmental PK parameters were not generated for Ramucirumab due to inadequate PK sampling.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose","groups":[{"id":"OG000","title":"All Parts - 750mg","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG001","title":"All Parts - 2000mg","description":"Participants received 8 mg/kg Ramucirumab followed by 2000 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies","description":"Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:10 for anti-ramucirumab antibodies).","populationDescription":"All participants who received at least one dose of ramucirumab and had evaluable immunogenicity samples.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Baseline through 46 Months","groups":[{"id":"OG000","title":"Part A - 750 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG001","title":"Part A - 2000 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 2000 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG002","title":"Part B - Gastric","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG003","title":"Part B - HCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG004","title":"Part B - RCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."},{"id":"OG005","title":"Part B - NSCLC","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 46 months","description":"All participants who received at least one dose of study drug. Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.","eventGroups":[{"id":"EG000","title":"Part A - 750 mg Emibetuzumab","description":"Participants received 8 milligram per kilogram (mg/kg) Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle.","deathsNumAffected":0,"deathsNumAtRisk":3,"seriousNumAffected":2,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG001","title":"Part A - 2000 mg Emibetuzumab","description":"Participants received 8 mg/kg Ramucirumab followed by 2000 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle.","deathsNumAffected":0,"deathsNumAtRisk":3,"seriousNumAffected":2,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG002","title":"Part B - Gastric","description":"Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle.","deathsNumAffected":3,"deathsNumAtRisk":16,"seriousNumAffected":4,"seriousNumAtRisk":16,"otherNumAffected":15,"otherNumAtRisk":16},{"id":"EG003","title":"Part B - HCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle.","deathsNumAffected":4,"deathsNumAtRisk":45,"seriousNumAffected":19,"seriousNumAtRisk":45,"otherNumAffected":45,"otherNumAtRisk":45},{"id":"EG004","title":"Part B - RCC","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle.","deathsNumAffected":1,"deathsNumAtRisk":15,"seriousNumAffected":5,"seriousNumAtRisk":15,"otherNumAffected":15,"otherNumAtRisk":15},{"id":"EG005","title":"Part B - NSCLC","description":"Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle.","deathsNumAffected":1,"deathsNumAtRisk":15,"seriousNumAffected":3,"seriousNumAtRisk":15,"otherNumAffected":14,"otherNumAtRisk":15}],"seriousEvents":[{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Oesophageal stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Clostridium difficile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Enterocolitis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hepatic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":16},{"groupId":"EG003","numEvents":9,"numAffected":7,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":6,"numAffected":2,"numAtRisk":15}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":9,"numAffected":7,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":15}]},{"term":"Eye discharge","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Periorbital oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":8,"numAffected":6,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":11,"numAffected":9,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":16},{"groupId":"EG003","numEvents":14,"numAffected":12,"numAtRisk":45},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG005","numEvents":6,"numAffected":5,"numAtRisk":15}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":16},{"groupId":"EG003","numEvents":12,"numAffected":11,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG005","numEvents":6,"numAffected":4,"numAtRisk":15}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Gingival swelling","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Intra-abdominal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Lip dry","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":15,"numAffected":8,"numAtRisk":16},{"groupId":"EG003","numEvents":16,"numAffected":12,"numAtRisk":45},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":15},{"groupId":"EG005","numEvents":6,"numAffected":4,"numAtRisk":15}]},{"term":"Proctalgia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Retching","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":4,"numAffected":3,"numAtRisk":15}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":11,"numAffected":6,"numAtRisk":16},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":7,"numAffected":5,"numAtRisk":15}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":16},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":15}]},{"term":"Breakthrough pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":20,"numAffected":11,"numAtRisk":16},{"groupId":"EG003","numEvents":34,"numAffected":25,"numAtRisk":45},{"groupId":"EG004","numEvents":7,"numAffected":6,"numAtRisk":15},{"groupId":"EG005","numEvents":13,"numAffected":9,"numAtRisk":15}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":15,"numAffected":6,"numAtRisk":16},{"groupId":"EG003","numEvents":38,"numAffected":26,"numAtRisk":45},{"groupId":"EG004","numEvents":9,"numAffected":5,"numAtRisk":15},{"groupId":"EG005","numEvents":9,"numAffected":5,"numAtRisk":15}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Bile duct obstruction","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":5,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Rubber sensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Infected cyst","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Mucosal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":15}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":15}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":15}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Activated partial thromboplastin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":15}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":45},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":4,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":7,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Blood calcium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":6,"numAffected":4,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":3,"numAffected":1,"numAtRisk":15}]},{"term":"Paracentesis","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":7,"numAffected":5,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":8,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":16},{"groupId":"EG003","numEvents":13,"numAffected":11,"numAtRisk":45},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":15},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":15}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":11,"numAffected":6,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":4,"numAffected":2,"numAtRisk":15}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":16},{"groupId":"EG003","numEvents":21,"numAffected":13,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":15}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":11,"numAffected":7,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":15}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":6,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":16},{"groupId":"EG003","numEvents":15,"numAffected":9,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":45},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG005","numEvents":5,"numAffected":3,"numAtRisk":15}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG005","numEvents":4,"numAffected":3,"numAtRisk":15}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Musculoskeletal disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Haemangioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":15},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":15}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":15}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Micturition urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Nocturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Urinary tract pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Breast mass","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":9}]},{"term":"Menorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":4},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":6}]},{"term":"Penile oedema","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":9}]},{"term":"Scrotal oedema","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":9}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":16},{"groupId":"EG003","numEvents":12,"numAffected":11,"numAtRisk":45},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":15},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":15}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":15}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":21,"numAffected":12,"numAtRisk":45},{"groupId":"EG004","numEvents":9,"numAffected":8,"numAtRisk":15},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":15}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Upper-airway cough syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":15}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Erythema multiforme","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Nail ridging","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Photosensitivity reaction","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Purpura","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":15}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Skin disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":30,"numAffected":11,"numAtRisk":45},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":15}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Jugular vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Lymphoedema","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":45},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":15}]},{"term":"Thrombophlebitis superficial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":15}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release \\& can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to sponsor for review. Sponsor can extend disclosure restriction for additional 60 days to protect intellectual property interests. If PI is unwilling to delay then PI shall remove the information that sponsor believes would jeopardize its IP interests"},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2015-03-13","uploadDate":"2019-01-30T09:41","filename":"Prot_000.pdf","size":990291},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2014-11-21","uploadDate":"2019-01-30T09:43","filename":"SAP_001.pdf","size":3032540}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D008113","term":"Liver Neoplasms"},{"id":"D002292","term":"Carcinoma, Renal Cell"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D008107","term":"Liver Diseases"},{"id":"D000230","term":"Adenocarcinoma"},{"id":"D002277","term":"Carcinoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D007680","term":"Kidney Neoplasms"},{"id":"D014571","term":"Urologic Neoplasms"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D007674","term":"Kidney Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000599789","term":"emibetuzumab"},{"id":"D000096662","term":"Ramucirumab"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}